Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Cloud-Based vs. In-House Electronic Health Records

Health organizations have been leveraging technology for some time to improve patient experiences and make workflows more efficient, and the central hub for clinicians to record, store and share data is their EHR. Many factors need to be considered when choosing the right EHR, including whether it’s cloud-based or on-site. The biggest difference between the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Health organizations have been leveraging technology for some time to improve patient experiences and make workflows more efficient, and the central hub for clinicians to record, store and share data is their EHR.

Many factors need to be considered when choosing the right EHR, including whether it’s cloud-based or on-site. The biggest difference between the two is where the data lives. In cloud-based EHRs, patient records live in an internet-based, on-demand network. On-premise EHRs require data to be hosted locally and housed on-site, which requires significant hardware investment.

So, which is right for your organization?

Cloud-Based EHRs Offer Many Advantages

The cloud has become a vital tool in how organizations use technology, and it provides many benefits for those who adopt it. Cloud-based EHRs are relatively popular, and a study from HIMSS revealed that about two-thirds of healthcare organizations use the cloud or cloud services. So, why have so many migrated to cloud-based EHRs?

The cloud presents multiple opportunities for healthcare entities to reduce costs, enhance security and improve interoperability.

Reduce Costs and Capital Investment

Setting up a new EHR can require substantial capital depending on your requirements, especially if you are responsible for hardware and upgrades. With a cloud-based EHR, you’ll reduce costs associated with EHR implementation, management, and storage.

Every time a new upgrade occurs, you won’t incur additional costs to enhance your servers. With the cloud, you are only paying for the storage that you need, and you don’t need additional IT resources.

Enhance Data Security

Keeping healthcare data safe is paramount and required by HIPAA and other privacy regulations. Moving to the cloud improves the security of your data. Cloud service providers deliver highly secure and well-protected data centers that easily thwart cyberattacks, mostly through tactics like encryption.

Having an on-site server means you are completely responsible for its security, which may be a hard task to ensure, especially for small healthcare entities that don’t have the resources.

Improve Interoperability for Better Patient Outcomes

The world of healthcare data places substantial emphasis on that the ability to share that data across applications. Healthcare interoperability is critical in the modern world, enabling greater access to information to improve patient care.

This data sharing must be secure and seamless, which is better accomplished by using the cloud. Interoperability boosts clinician satisfaction with EHRs, which is much harder to execute with on-premise EHRs.

On-premise applications suffer from poor usability, hampering the ability to exchange data. Cloud-based applications can be a huge help in overcoming interoperability barriers, which, in turn, improves patient outcomes.

Your EHR Should Deliver Advantages, Not Obstacles

Your EHR solution is one of your most valuable tools. Being stuck with on-premise systems is keeping you from realizing multiple benefits.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512